UTAA07
/ PersonGen Biomedicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 11, 2021
CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
(clinicaltrials.gov)
- P1; N=8; Recruiting; Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Clinical • New P1 trial • Oncology
1 to 1
Of
1
Go to page
1